Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Science in Sport shifts operating model to focus of profitability

(Sharecast News) - Performance nutrition company Science in Sport updated the market on a significant shift in its operating model on Wednesday, following a comprehensive business review. The AIM-traded firm said its new leadership team, in place since the fourth quarter of 2023, had noted past strategic missteps that led to an inflated cost structure and the prioritising of revenue growth over profitability.

To address those issues, Science in Sport said it was implementing several key actions.

It had streamlined its executive team by eliminating senior roles, and was also reassessing overseas distribution agreements while emphasising securing and growing profitable revenue streams.

Additionally, supplier relationships and product inventory were being reviewed for further optimisation.

Marketing spend would be closely tied to measurable commercial results, with significant cost savings already achieved and further efficiencies expected in 2024.

Despite lower revenues in 2023, Science in Sport said it delivered EBITDA in line with market expectations.

The company's focus on cash and profit resulted in improved margins during the final quarter of the year.

It said that, while 2024 revenue was expected to remain broadly flat, it anticipated a doubling of underlying EBITDA and a reduction in net debt.

At 1338 GMT, shares in Science in Sport were down 2.69% at 16.3p.

Reporting by Josh White for Sharecast.com.

Share this article

Related Sharecast Articles

AstraZeneca makes progress with two breast cancer treatments
(Sharecast News) - AstraZeneca issued favourable updates on two of its breast cancer treatments on Monday - 'Truqap', or capivasertib, and 'Enhertu', or trastuzumab deruxtecan - following encouraging results from respective phase three trials.
Insurer Beazley keeps guidance after solid Q1 premiums growth
(Sharecast News) - Insurance group Beazley said that first-quarter results were in line with guidance with insurance written premiums (IWP) growing at high single digits.
Blackstone ups bid for Hipgnosis with $1.57bn offer
(Sharecast News) - Music rights owner Hipgnosis said it it agreed terms on a £1.2bn takeover by private equity investor Blackstone, in the latest tit-for-tat battle with rival Concord.
Aukett Swanke flags delays to some contracts
(Sharecast News) - Smart buildings, architectural and design services specialist Aukett Swanke said in an update on Friday that, as outlined in its recent financial statements, it maintained a robust pipeline of interest, although a number of projects had been pushed back.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.